Abstract
Positron emission tomography (PET) enables strong binding site-radioligand interactions to be studied in vivo. This capability may be exploited to gain new insights into changes in the distribution, density, affinity and occupation of enzymes and neurotransmitter receptors in relation to the progress of disease, or to investigate the action of novel therapeutics with regard to their site(s) of action, effective dose and duration of action. The strong binding site-radioligand interactions tend to be enantioselective (see Lehmann, 1986) and if so demand the use of a homochiral radioligand, usually the more potent enantiomer (the eutomer). The reasons may be summarised as follows:
-
i)
to avoid the confusing effects of any differential distribution, metabolism, protein binding or pharmacokinetics in the enantiomers of a racemic radioligand. For reviews of such effects in pharmacology, see Simonyi et al. (1986), Testa (1986) and Walle and Walle (1986).
-
ii)
to achieve optimal signal-to-noise ratio (e.g. specific/nonspecific radioligand binding) by avoiding contributions to non-specific binding by the less potent enantiomer (the distomer).
-
iii)
to obtain kinetic data that can be modelled mathematically to provide meaningful quantitative measurements on binding site populations (e.g. binding potential, KD or Bmax values). For relevant pharmacokinetic discussion see Ariëns (1986) and references therein.
-
iv)
to avoid unnecessary radiation exposure from the distomer.
This is a preview of subscription content, log in via an institution to check access.
Access this chapter
Tax calculation will be finalised at checkout
Purchases are for personal use only
Preview
Unable to display preview. Download preview PDF.
References
Affolter, H., Hertel, C., Jaeggi, K., Portenier, M., and Staehelin, M., 1985, (-)-S-[3H]CGP-12177 and its use to determine the rate constants of unlabeled Ăź-adrenergic antagonists, Proc. Natl Acad. Sci. USA, 82:925.
Aigbirhio, F.I., Pike, V.W., Francotte, E., Waters, S.L., Banfield, B., Jaeggi, K.A., and Drake, A., 1992, 5-[1-(2,3-Diaminophenoxy)]-3′-(N-r-butylamino)propan-2′-ol — simplified asymmetric synthesis with CD and chiral HPLC analysis, Tetrahedron: Asymmetry, 3:539.
Aigbirhio, F.I., Pike, V.W., Francotte, E., Jaeggi, K., and Waters, S.L., 1993, Simplified asymmetric synthesis for S-[carbonyl- 11 C]CGP 12177 production, J. Label. Compd. Radiopharm., 32:159.
Ariëns, E.J., 1986, Chirality in bioactive agents and its pitfalls, TiPs, 7:200.
Baldwin, J. J., Hirschman, R., Lumma P.K., Lumma, W.C., Jr., and Ponticello, G.S., 1977, An approach to peripheral vasodilator-β-adrenergic blocking agents, J. Med. Chem., 20:1024.
Berthod, A., Liang Jin, H., Beesley, T.E., Duncan, J.D., and Armstrong, D.W., 1990, Cyclodextrin chiral stationary phases for liquid chromatographic separations of drug stereoisomers, J. Pharmaceut. & Biomed. Analysis, 8:123.
Boullais, C., Crouzel, C., and Syrota, A., 1985, Synthesis of 4-(3-t-butylamino-2-hydroxypropoxy) benzimidazol-2(11C)-one (CGP 12177), J. Label. Compd. Radiopharm., 23:565.
Brady, F., Luthra, S.K., Tochon-Danguy, H., Landais, P.G., Waters, S.L., Law, M., Jaeggi, K.A., and Pike, V.W., 1990, Towards a chiral precursor for the automated radiosynthesis of carbon-11 labelled 5-CGP 12177, J. Label. Compd. Radiopharm., 30:251.
Brady, F., Luthra, S.K., Tochon-Danguy, H-J., Steel, C.J., Waters, S.L., Kensett, M.J., Landais, P.G., Shah, F., Jaeggi, K.A., Drake, A., Clark, J.C., and Pike, V.W., 1991, Asymmetric synthesis of a precursor for the automated radiosynthesis of 5-(3’-r-butylamino-2’-hydroxypropoxy)-benzimidazol-2-[11C]one (S-[11C]CGP 12177) as a preferred radioligand for β-adrenergic receptors, Appl. Radiat. Isot., 42:621.
Camsonne, R., Crouzel, C., Comar, D., Mazière, M., Prenant, C., Sastre, J., Moulin, M.A., and Syrota, A., 1984, Synthesis of N-(11C)methyl, N-(methyl-l propyl), (chloro-2 phenyl)-1 isoquinoline carboxamide-3 (PK 11195): a new ligand for peripheral benzodiazepine receptors, J. Label. Compd. Ratiopharm., 21:985.
Charbonneau, P., Syrota, A., Crouzel, C., Valois, J.M., Prenant, C., and Crouzel, C., 1986, Peripheral type benzodiazepine receptors in the living heart characterised by positron emission tomography, Circulation, 73:476.
Cremer, J. E., Hume, S.P., Cullen, B.M., Myers, R., Manjil, L.G., Turton, D.R., Luthra, S.K., Bateman, D.M., and Pike, V.W., 1992, The distribution of radioactivity in brains of rats given [N-methyl- 11 C]PK 11195 in vivo after induction of a cortical ischaemic lesion, Nucl. Med. Biol., 19:159.
Dubroeucq, M-C., Renault, C., and Le Fur, G.R, 1983, Nouveau dérivés d’arène et d’hétéroarènecarboxamides, leur procédes de préparation et médicaments les contenant, European Patent No, 0094271.
Hammadi, A., and Crouzel, C., 1990, Stereoselective synthesis of the (R)- and (S)-2-(2-amino-3-nitrophenoxy)-3-(tert-butylamino)-2-propanol from the enantiomeric glycidyl tosylates, Tetrahedron: Asymmetry, 1:579.
Hammadi, A., and Crouzel, C., 1991, Asymmetric synthesis of (2S)-and (2R)-4-(3-t-butylamino-2-hydroxypropoxy)-benzidazol-2-[11C]-one ((S)-and (R)-[HC]-CGP 12177 from optically active precursors, J. Label. Compd. Radiopharm., 29:681.
Hudson, A.L., Mallard, N.J., Tyacke, R., and Nutt, D.J., 1992, pH]-RX821002: a highly selective ligand for the identification of α2-adrenoceptors in the rat brain, Molecular Neuropharmacol., 1:219.
Hume, S.P., Lammertsma, A.A., Opacka-Juffry, J., Ahier, R.G., Myers, R., Cremer, J.E., Hudson, A.L., Nutt, D.J., and Pike, V.W., 1992, Quantification of in vivo binding of pH]RX 821002 in rat brain: evaluation as a radioligand for central α2-adrenoceptors, Nucl. Med. Biol., 19:841.
Georges, G., Vercauteren, D.P., Vanderveken, D.J., Horion, R., Evrard G., Fripiat J.G., Andre J-M., and Durant F., Structural and electronic analysis of peripheral benzodiazepine lignads: description of the pharmacophore elements for their receptors, Int. J. Quantum Chem: Quantum Biol. Symp., 1990, 17:1.
Klunder, J.M., Onami, T., and Sharpless, K.B, 1989, Arenesulfonate derivatives of homochiral glycidol: versatile chiral building blocks for organic synthesis, J. Org. Chem., 54:1295.
Kuhn, W., 1933, in Stereochemie p. 317, Freudenberg K. (Ed.), F. Deuticke, Liepzig.
Landais, P., and Crouzel C., 1987, A new synthesis of carbon-11 labelled phosgene, Appl. Radiat. Isot., 38:297.
Langin, D., Lafontan, M., Stillings, M.R., and Paris, H., 1989, [3H]RX821002: a new tool for the identification of α2A-adrenoceptors, Eur. J. Pharmacol., 167:95.
Law, M.P., 1993, Demonstration of the suitability of CGP 12177 for in vivo studies of Ăź-adrenoreceptors, Br. J. Pharmacol., In press.
Law, M.P. and Burgin, J., 1989, Evaluation of CGP-12177 for characterization of beta-adrenergic receptors by PET: in vivo studies in rat, J. Nucl. Med., 30:766.
Lehmann, P.A., 1986, Stereoisomerism and drug action, TiPS, 7:281.
Mason, S.F., 1963, Quart. Rev. Chem. Soc., 17:20.
McClure, D.E., Arison, B.H., and Baldwin, J.J., 1979, Mode of nucleophilic addition to epichlorhydrin and related species: chiral aryloxymethyloxiranes, J. Am. Chem. Soc., 101:3666.
Myers, R., Manjil, L.G., Cullen, B.M., Price, G.W., Frackowiak, R.S.J., and Cremer, J.E., 1991, Macrophage and astrocyte populations in relation to [3H]PK 11195 binding in rat cerebral cortex following a local ischaemic lesion, J. Cerebr. Blood Flow Metab., 11:314.
Newman, A.H., Lueddens, H.W.M., Skolnick, P., and Rice K.C., 1987, Novel irreversible ligands specific for “peripheral” type benzodiazepine receptors: (±)-, (+)-, and (-)-1-(2-chlorophenyl)-N-(1-methylpropyl)-N-(2-isothiocyanatoethyl)-3-isoquinolinecarboxamide and l-(2-isothiocyanoethyl)-7-chloro-1,3-dihydro-5-(4-chlorophenyl)-2H-1,4-benzodiazepin-2-one, J. Med. Chem., 30:1901.
Pike, V.W., Halldin, C., Crouzel, C., Barré, L., Nutt, D.J., Osman, S., Shah, F., Turton, D.R., and Waters S.L., 1993a, Radioligands for PET studies of central benzodiazepine receptors and PK (peripheral benzodiazepine) binding sites — current status, Nucl. Med. Biol, 20:503.
Pike, V.W., Hume, S.P., Aigbirhio, F.I., Turton, D.R., and Nutt D.J., 1993b, [11C]RX 821002 as a potential PET radioligand for central α2 adrenoceptors, J. Label. Compd. Radiopharm., 32:495.
Seto, M., Syrota, A., Crouzel, C., Charbonneau, P., Vallois, J.M., Cayla, J., and Boullais, C., 1986, Beta adrenergic receptors in dog heart characterised by 11C-CGP 12177 and PET, J. Nucl Med., 27:949.
Shah, F., Pike, V.W., and Turton, D.R., 1993, Syntheses of homochiral 11C-labelled radioligands for peripheral benzodiazepine binding sites, J. Label Compd. Radiopharm., 32:166.
Simonyi, M., Fitos I., and Visy, J., 1986, Chirality of bioactive agents in protein binding and storage transport processes, TiPS, 7:112.
Staehelin, M., and Hertel, C., 1983, pH]CGP-12177, A β-adrenergic ligand suitable for measuring cell surface receptors, J. Receptor Res., 3:35.
Staehelin, M., Simons P., Jaeggi, K., and Wigger, N., 1983, CGP-12177 A hydrophilic β-adrenergic receptor radioligand reveals high affinity binding of agonists to intact cells, J. Biol Chem., 258:3496.
Syrota A., 1988, Receptor bindng studies of the intact heart, In New Concepts in Cardiac Imaging, No 4, Chapter 6, p. 141, Year Book Medical Publishers, Chicago.
Testa, B., 1986, Chiral aspects of drug metabolism, TiPS, 7:60.
Vauquelin, G., De Vos, H., De Backer, J-P., and Ebinger, G., 1990, Identification of α2 adrenergic receptors in human frontal cortex membranes by binding of [3H]RX 821002, the 2-methoxy analog of [3H]idazoxan, Neurochem. Int., 17:537.
Walle, T., and Walle, U.K., 1986, Pharmacokinetic parameters obtained with racemates, TiPS, 7:155.
Welbourn, A.P., Chapleo, C.B., Lane, A.C., Myers, P.L., Roach, A.G., Smith, C.F.C., Stillings, M.R., and Tulloch, I.A., 1986, α-Adrenoceptor reagents. 4. Resolution of some potent selective prejunctional α2-adrenoceptor antagonists, J. Med. Chem., 29:2000.
Author information
Authors and Affiliations
Editor information
Editors and Affiliations
Rights and permissions
Copyright information
© 1995 Springer Science+Business Media New York
About this chapter
Cite this chapter
Pike, V.W. et al. (1995). Homochiral Radioligands for PET: Aspects of Asymmetric Synthesis, Analysis and Behaviour In Vivo . In: Emran, A.M. (eds) Chemists’ Views of Imaging Centers. Springer, Boston, MA. https://doi.org/10.1007/978-1-4757-9670-4_51
Download citation
DOI: https://doi.org/10.1007/978-1-4757-9670-4_51
Publisher Name: Springer, Boston, MA
Print ISBN: 978-1-4757-9672-8
Online ISBN: 978-1-4757-9670-4
eBook Packages: Springer Book Archive